Top

Published in:

01-06-2015 | Preclinical Study

miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer

Authors: Yunhui Hu, Kun Xu, Ernesto Yagüe

Published in: Breast Cancer Research and Treatment | Issue 2/2015

Abstract

Multidrug resistance (MDR) remains one of the most significant obstacles in breast cancer treatment, and this process often involves dysregulation of a great number of microRNAs (miRNAs). Some miRNAs are indicators of drug resistance and confer resistance to chemotherapeutic drugs, although our understanding of this complex process is still incomplete. We have used a combination of miRNA profiling and real-time PCR in two drug-resistant derivatives of MCF-7 and Cal51 cells. Experimental modulation of miR expression has been obtained by retroviral transfection. Taxol and doxorubicin IC50 values were obtained by short-term drug sensitivity assays. Apoptosis was determined by flow cytometry after annexin V staining, by caspase 3/7 and caspase 9 activity assays and the levels of apoptosis-related proteins bcl-2 and bax by real-time PCR and Western blot. miR target was studied using transient transfection of luciferase constructs with the 3′ untranslated regions (UTR) of target mRNAs. Small interfering RNA-mediated genetic knock-down was performed in MDR cells and its modulatory effect on apoptosis examined. The effect of miRNA on tumorigenicity and tumor drug response was studied in mouse xenografts. miRNA profiling of two drug-resistant breast cancer cell models indicated that miR-218 was down-regulated in both MCF-7/A02 and CALDOX cells. Ectopic expression of miR-218 resensitized both drug-resistant cell lines to doxorubicin and taxol due to an increase in apoptosis. miR-218 binds survivin (BIRC5) mRNA 3′-UTR and down-regulated reporter luciferase activity. Experimental down-regulation of survivin by RNA interference in drug-resistant cells did mimic the sensitization observed when miRNA-218 was up-regulated. In addition, resensitization to taxol was also observed in mouse tumor xenografts from cells over-expressing miR-218. miR-218 is involved in the development of MDR in breast cancer cells via targeting survivin and leading to evasion of apoptosis. Targeting miR-218 and survivin may thus provide a potential strategy for reversing drug resistance in breast cancer.

Available only for authorised users

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138 CrossRefPubMed

Gu J, Fang X, Hao J, Sha X (2015) Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Biomaterials 45:99–114. doi:10.1016/j.biomaterials.2014.12.030 CrossRefPubMed

Naci D, El Azreq MA, Chetoui N, Lauden L, Sigaux F, Charron D, Al-Daccak R, Aoudjit F (2012) Alpha2beta1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem 287(21):17065–17076. doi:10.1074/jbc.M112.349365 CrossRefPubMedCentralPubMed

Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71(5):1858–1870. doi:10.1158/0008-5472.CAN-10-3604 CrossRefPubMedCentralPubMed

Korner C, Keklikoglou I, Bender C, Worner A, Munstermann E, Wiemann S (2013) MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J Biol Chem 288(12):8750–8761. doi:10.1074/jbc.M112.414128 CrossRefPubMedCentralPubMed

Yahya SM, Elsayed GH (2014) A summary for molecular regulations of miRNAs in breast cancer. Clin Biochem. doi:10.1016/j.clinbiochem.2014.12.013 PubMed

Farazi TA, Spitzer JI, Morozov P, Tuschl T (2011) miRNAs in human cancer. J Pathol 223(2):102–115. doi:10.1002/path.2806 CrossRefPubMedCentralPubMed

Greve TS, Judson RL, Blelloch R (2013) microRNA control of mouse and human pluripotent stem cell behavior. Annu Rev Cell Dev Biol 29:213–239. doi:10.1146/annurev-cellbio-101512-122343 CrossRefPubMed

Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y, Song E (2011) Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17(22):7105–7115CrossRefPubMed

10.

Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL (2013) MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 12:23. doi:10.1186/1476-4598-12-23 CrossRefPubMedCentralPubMed

11.

Chen DQ, Pan BZ, Huang JY, Zhang K, Cui SY, De W, Wang R, Chen LB (2014) HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells. Oncotarget 5(10):3333–3349PubMedCentralPubMed

12.

He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Sung JJ, Yu J (2012) MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med 18:1491–1498. doi:10.2119/molmed.2012.00304 PubMedCentral

13.

Li J, Ping Z, Ning H (2012) miR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci 13(12):16053–16064. doi:10.3390/ijms131216053 CrossRefPubMedCentralPubMed

14.

Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K, Inazawa J (2011) The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 71(17):5765–5778. doi:10.1158/0008-5472.CAN-11-0368 CrossRefPubMed

15.

Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL (2014) Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol 20(22):6906–6911. doi:10.3748/wjg.v20.i22.6906 CrossRefPubMedCentralPubMed

16.

Li Q, Zhu F, Chen P (2012) miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun 424(1):28–33. doi:10.1016/j.bbrc.2012.06.028 CrossRefPubMed

17.

He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H, Zhang X (2014) miR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biol. doi:10.1007/s13277-014-2814-z

18.

Raguz S, Adams C, Masrour N, Rasul S, Papoutsoglou P, Hu Y, Cazzanelli G, Zhou Y, Patel N, Coombes C, Yague E (2013) Loss of O(6)-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochem Pharmacol 85(2):186–196. doi:10.1016/j.bcp.2012.10.020 CrossRefPubMed

19.

Zhou Y, Hu Y, Yang M, Jat P, Li K, Lombardo Y, Xiong D, Coombes RC, Raguz S, Yague E (2014) The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death Differ 21(3):462–474. doi:10.1038/cdd.2013.167 CrossRefPubMedCentralPubMed

20.

Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y, Zhang Y, Yague E, Xiong D (2014) Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat 143(2):287–299. doi:10.1007/s10549-013-2809-2 CrossRefPubMed

21.

Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng T, Yang M, Xiong D (2013) Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol 72(4):789–798CrossRefPubMed

22.

Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill RP, Zahedi P, Yip KW, Liu FF (2015) The microRNA-218~survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget 6(2):1090–1100PubMedCentralPubMed

23.

Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O’Sullivan B, Liu FF (2011) miR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 71(6):2381–2391. doi:10.1158/0008-5472.CAN-10-2754 CrossRefPubMed

24.

Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22(11):2729–2740. doi:10.1093/emboj/cdg263 CrossRefPubMedCentralPubMed

25.

Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279(33):34087–34090. doi:10.1074/jbc.C400236200 CrossRefPubMed

26.

Wang S, Huang X, Lee CK, Liu B (2010) Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29(29):4225–4236. doi:10.1038/onc.2010.180 CrossRefPubMed

27.

Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Res Updat 5(2):65–72CrossRef

28.

Pennati M, Folini M, Zaffaroni N (2008) Targeting survivin in cancer therapy. Exp Opin Ther Targets 12(4):463–476. doi:10.1517/14728222.12.4.463 CrossRef

29.

Greinacher A, Selleng K (2010) Thrombocytopenia in the intensive care unit patient. Am Soc Hematol Edu Prog 2010:135–143. doi:10.1182/asheducation-2010.1.135 CrossRef

30.

Baytekin F, Tuna B, Mungan U, Aslan G, Yorukoglu K (2011) Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. Urologic oncology 29(5):502–507. doi:10.1016/j.urolonc.2009.09.001 CrossRefPubMed

31.

Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278(25):23130–23140. doi:10.1074/jbc.M300957200 CrossRefPubMed

32.

Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283(44):29897–29903. doi:10.1074/jbc.M804612200 CrossRefPubMedCentralPubMed

33.

Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D (2013) MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 434(3):688–694. doi:10.1016/j.bbrc.2013.04.010 CrossRefPubMed

34.

Liang Z, Li Y, Huang K, Wagar N, Shim H (2011) Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 28(12):3091–3100. doi:10.1007/s11095-011-0570-y CrossRefPubMedCentralPubMed

35.

Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P (2014) Loss of p53 and altered miR15-a/16-1short right arrowMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 28(1):118–128. doi:10.1038/leu.2013.125 CrossRefPubMedCentralPubMed

36.

Cai CK, Zhao GY, Tian LY, Liu L, Yan K, Ma YL, Ji ZW, Li XX, Han K, Gao J, Qiu XC, Fan QY, Yang TT, Ma BA (2012) miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep 28(5):1764–1770. doi:10.3892/or.2012.1995 PubMed

37.

Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA (2008) Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27(18):2575–2582. doi:10.1038/sj.onc.1210919 CrossRefPubMedCentralPubMed

38.

Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11(3):R27. doi:10.1186/bcr2257 CrossRefPubMedCentralPubMed

39.

Zhang XL, Shi HJ, Wang JP, Tang HS, Wu YB, Fang ZY, Cui SZ, Wang LT (2014) MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol 20(32):11347–11355. doi:10.3748/wjg.v20.i32.11347 CrossRefPubMedCentralPubMed

40.

Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711):580–584. doi:10.1038/25141 CrossRefPubMed

41.

Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8(1):61–70. doi:10.1038/nrc2293 CrossRefPubMed

42.

Kanwar JR, Kamalapuram SK, Kanwar RK (2013) Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev 33(4):765–789. doi:10.1002/med.21264 CrossRefPubMed

43.

Singh N, Krishnakumar S, Kanwar RK, Cheung CH, Kanwar JR (2014) Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov Today. doi:10.1016/j.drudis.2014.11.013

44.

Nabilsi NH, Broaddus RR, Loose DS (2009) DNA methylation inhibits p53-mediated survivin repression. Oncogene 28(19):2046–2050. doi:10.1038/onc.2009.62 CrossRefPubMed

45.

Huang J, Lyu H, Wang J, Liu B (2015) MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res 5(1):20–31PubMedCentralPubMed

46.

Wu DW, Cheng YW, Wang J, Chen CY, Lee H (2010) Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 70(24):10392–10401. doi:10.1158/0008-5472.CAN-10-2341 CrossRefPubMed

47.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67(17):8014–8021. doi:10.1158/0008-5472.CAN-07-1343 CrossRefPubMed

48.

Holmes D (2012) Cancer drug’s survivin suppression called into question. Nat Med 18(6):842–843. doi:10.1038/nm0612-842b CrossRefPubMed

49.

Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36 (Database issue):D149–153. doi:10.1093/nar/gkm995

Title: miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer
Authors: Yunhui Hu
Kun Xu
Ernesto Yagüe
Publication date: 01-06-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3372-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis

Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

Exome sequencing of contralateral breast cancer identifies metastatic disease

Weight lifting and appendicular skeletal muscle mass among breast cancer survivors: a randomized controlled trial

A framework for the role of acute inflammation in tumor progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer